Insider trading activities (stock purchases, sales, and option exercises)
reported by insiders of Ionis Pharmaceuticals Inc (IONS)
since 2015 are shown in Table 1 and Table 2.
Table 1 shows the monthly insider trading data of Ionis Pharmaceuticals Inc.
Table 2 shows the detailed insider transactions.
This company's CIK number is 874015.
Total stock buying since 2015: $477,900.
Total stock sales since 2015: $209,463,995.
Total stock option exercises since 2015: $78,074,596.
Table 3. Detailed insider trading at Ionis Pharmaceuticals Inc (IONS)
| Trade Date |
Insider Name |
Trade Type |
Shares |
Price ($) |
Value ($) |
| 2025-09-03 | Devers Shannon L. (EVP, Chief Human Resources Ofc) | Sale | 3,162 | 61.02 | 192,942 |
| 2025-09-03 | Devers Shannon L. (EVP, Chief Human Resources Ofc) | Option Ex | 3,162 | 35.09 | 110,954 |
| 2025-09-03 | Schneider Eugene (EVP, Chf Clinical Develop Ofcr) | Sale | 19,658 | 60.94 | 1,197,938 |
| 2025-09-03 | Schneider Eugene (EVP, Chf Clinical Develop Ofcr) | Option Ex | 19,658 | 53.77 | 1,057,010 |
| 2025-09-03 | Baroldi Joseph (EVP, Chief Business Officer) | Sale | 32,800 | 60.55 | 1,985,974 |
| 2025-09-03 | Baroldi Joseph (EVP, Chief Business Officer) | Option Ex | 32,800 | 31.80 | 1,043,040 |
| 2025-09-03 | O'neil Patrick R. (EVP CLO & General Counsel) | Sale | 76,850 | 61.16 | 4,699,761 |
| 2025-09-03 | O'neil Patrick R. (EVP CLO & General Counsel) | Option Ex | 76,850 | 41.32 | 3,175,211 |
| 2025-09-03 | Monia Brett P (Chief Executive Officer) | Sale | 203,814 | 60.10 | 12,250,240 |
| 2025-09-03 | Monia Brett P (Chief Executive Officer) | Option Ex | 203,814 | 39.14 | 7,976,668 |
| 2025-09-03 | Loscalzo Joseph (Director) | Sale | 16,000 | 60.15 | 962,368 |
| 2025-09-03 | Loscalzo Joseph (Director) | Option Ex | 16,000 | 24.42 | 390,720 |
| 2025-09-03 | Klein Joseph Iii (Director) | Sale | 56,000 | 60.00 | 3,360,000 |
| 2025-09-03 | Klein Joseph Iii (Director) | Option Ex | 56,000 | .00 | 0 |
| 2025-09-03 | Bennett C Frank (EVP, Chief Scientific Officer) | Sale | 33,909 | 60.62 | 2,055,563 |
| 2025-09-03 | Bennett C Frank (EVP, Chief Scientific Officer) | Option Ex | 59,691 | 57.63 | 3,440,290 |
| 2025-09-03 | Wender Joseph H (Director) | Sale | 22,400 | 60.14 | 1,347,090 |
| 2025-09-02 | Swayze Eric (EVP Research) | Sale | 11,130 | 51.45 | 572,649 |
| 2025-09-02 | O'neil Patrick R. (EVP CLO & General Counsel) | Sale | 13,050 | 54.52 | 711,420 |
| 2025-09-02 | O'neil Patrick R. (EVP CLO & General Counsel) | Option Ex | 13,050 | 32.60 | 425,430 |
| 2025-09-02 | Geary Richard S (EVP, Chief Development Officer) | Sale | 10,000 | 50.37 | 503,670 |
| 2025-09-02 | Bennett C Frank (EVP, Chief Scientific Officer) | Sale | 5,000 | 49.14 | 245,700 |
| 2025-09-02 | Parshall B Lynne (Director) | Sale | 20,000 | 50.95 | 1,019,100 |
| 2025-09-02 | Wender Joseph H (Director) | Sale | 33,600 | 56.28 | 1,891,176 |
| 2025-08-22 | Diaz Allene M. (Director) | Sale | 1,427 | 42.53 | 60,687 |
| 2025-08-18 | Bennett C Frank (EVP, Chief Scientific Officer) | Sale | 10,000 | 43.98 | 439,780 |
| 2025-08-18 | Bennett C Frank (EVP, Chief Scientific Officer) | Option Ex | 10,000 | 32.60 | 326,000 |
| 2025-08-06 | Parshall B Lynne (Director) | Sale | 5,000 | 42.25 | 211,240 |
| 2025-08-05 | Geary Richard S (EVP, Chief Development Officer) | Sale | 10,000 | 42.86 | 428,590 |
| 2025-08-04 | Schneider Eugene (EVP, Chf Clinical Develop Ofcr) | Sale | 9,549 | 42.80 | 408,697 |
| 2025-07-30 | Monia Brett P (Chief Executive Officer) | Sale | 2,432 | 45.00 | 109,440 |
| 2025-07-30 | Monia Brett P (Chief Executive Officer) | Option Ex | 2,432 | 32.60 | 79,283 |
| 2025-07-15 | Diaz Allene M. (Director) | Option Ex | 12,237 | .00 | 0 |
| 2025-07-15 | Yang Michael J. (Director) | Option Ex | 12,237 | .00 | 0 |
| 2025-07-15 | Hayden Michael R (Director) | Option Ex | 12,237 | .00 | 0 |
| 2025-07-15 | Loscalzo Joseph (Director) | Option Ex | 12,237 | .00 | 0 |
| 2025-07-15 | Herman Joan E (Director) | Option Ex | 12,237 | .00 | 0 |
| 2025-07-15 | Berthelsen Spencer R (Director) | Option Ex | 12,237 | .00 | 0 |
| 2025-07-15 | Parshall B Lynne (Director) | Option Ex | 12,237 | .00 | 0 |
| 2025-07-15 | Wender Joseph H (Director) | Option Ex | 12,237 | .00 | 0 |
| 2025-07-11 | Monia Brett P (Chief Executive Officer) | Sale | 1,160 | 41.74 | 48,416 |
| 2025-05-01 | Hayden Michael R (Director) | Buy | 15,000 | 31.86 | 477,900 |
| 2025-04-16 | Birchler Brian (EVP, Corp and Development Ops) | Sale | 680 | 28.37 | 19,291 |
| 2025-04-16 | Baroldi Joseph (EVP, Chief Business Officer) | Sale | 3,928 | 28.40 | 111,555 |
| 2025-04-16 | Jenne Kyle (EVP, Chf GL Pdt Str Ofcr) | Sale | 3,016 | 28.36 | 85,533 |
| 2025-04-15 | Birchler Brian (EVP, Corp and Development Ops) | Option Ex | 1,875 | .00 | 0 |
| 2025-04-15 | Baroldi Joseph (EVP, Chief Business Officer) | Option Ex | 10,837 | .00 | 0 |
| 2025-04-15 | Jenne Kyle (EVP, Chf GL Pdt Str Ofcr) | Option Ex | 12,226 | .00 | 0 |
| 2025-03-11 | Monia Brett P (Chief Executive Officer) | Sale | 140 | 32.32 | 4,524 |
| 2025-02-20 | O'neil Patrick R. (EVP CLO & General Counsel) | Sale | 1,207 | 32.35 | 39,046 |
| 2025-02-04 | O'neil Patrick R. (EVP CLO & General Counsel) | Sale | 6,165 | 31.62 | 194,937 |
| 2025-02-04 | Monia Brett P (Chief Executive Officer) | Sale | 38,843 | 31.65 | 1,229,458 |
| 2025-01-31 | Schneider Eugene (EVP, Chf Clinical Develop Ofcr) | Sale | 1,484 | 32.20 | 47,780 |
| 2025-01-31 | Swayze Eric (EVP Research) | Sale | 1,367 | 32.31 | 44,162 |
| 2025-01-31 | O'neil Patrick R. (EVP CLO & General Counsel) | Sale | 1,406 | 32.49 | 45,685 |
| 2025-01-31 | Monia Brett P (Chief Executive Officer) | Sale | 13,242 | 32.45 | 429,649 |
| 2025-01-31 | Geary Richard S (EVP, Chief Development Officer) | Sale | 1,406 | 32.41 | 45,561 |
| 2025-01-31 | Hougen Elizabeth L (EVP, Finance & CFO) | Sale | 1,523 | 32.44 | 49,403 |
| 2025-01-31 | Bennett C Frank (EVP, Chief Scientific Officer) | Sale | 1,327 | 32.46 | 43,079 |
| 2025-01-16 | Devers Shannon L. (EVP, Chief Human Resources Ofc) | Sale | 4,267 | 32.78 | 139,855 |
| 2025-01-16 | Birchler Brian (EVP, Corp and Development Ops) | Sale | 5,400 | 32.70 | 176,580 |
| 2025-01-16 | Schneider Eugene (EVP, Chf Clinical Develop Ofcr) | Sale | 6,523 | 32.79 | 213,889 |
| 2025-01-16 | Baroldi Joseph (EVP, Chief Business Officer) | Sale | 4,430 | 32.70 | 144,861 |
| 2025-01-16 | Swayze Eric (EVP Research) | Sale | 7,176 | 32.77 | 235,171 |
| 2025-01-16 | O'neil Patrick R. (EVP CLO & General Counsel) | Sale | 7,360 | 32.83 | 241,628 |
| 2025-01-16 | Monia Brett P (Chief Executive Officer) | Sale | 33,445 | 32.63 | 1,091,444 |
| 2025-01-16 | Geary Richard S (EVP, Chief Development Officer) | Sale | 7,072 | 32.86 | 232,407 |
| 2025-01-16 | Hougen Elizabeth L (EVP, Finance & CFO) | Sale | 8,870 | 32.81 | 290,989 |
| 2025-01-16 | Bennett C Frank (EVP, Chief Scientific Officer) | Sale | 6,752 | 32.90 | 222,113 |
| 2025-01-15 | Devers Shannon L. (EVP, Chief Human Resources Ofc) | Option Ex | 12,295 | .00 | 0 |
| 2025-01-15 | Birchler Brian (EVP, Corp and Development Ops) | Option Ex | 14,283 | .00 | 0 |
| 2025-01-15 | Schneider Eugene (EVP, Chf Clinical Develop Ofcr) | Option Ex | 17,372 | .00 | 0 |
| 2025-01-15 | Baroldi Joseph (EVP, Chief Business Officer) | Option Ex | 11,247 | .00 | 0 |
| 2025-01-15 | Swayze Eric (EVP Research) | Option Ex | 19,160 | .00 | 0 |
| 2025-01-15 | Yang Michael J. (Director) | Option Ex | 1,931 | .00 | 0 |
| 2025-01-15 | O'neil Patrick R. (EVP CLO & General Counsel) | Option Ex | 19,690 | .00 | 0 |
| 2025-01-15 | Monia Brett P (Chief Executive Officer) | Option Ex | 73,448 | .00 | 0 |
| 2025-01-15 | Geary Richard S (EVP, Chief Development Officer) | Option Ex | 18,901 | .00 | 0 |
| 2025-01-15 | Hougen Elizabeth L (EVP, Finance & CFO) | Option Ex | 23,887 | .00 | 0 |
| 2025-01-15 | Bennett C Frank (EVP, Chief Scientific Officer) | Option Ex | 18,011 | .00 | 0 |
| 2024-11-12 | Swayze Eric (EVP Research) | Sale | 1,194 | 37.92 | 45,277 |
| 2024-11-12 | Monia Brett P (Chief Executive Officer) | Sale | 6,630 | 38.05 | 252,291 |
| 2024-11-12 | Loscalzo Joseph (Director) | Sale | 13,508 | 37.86 | 511,426 |
| 2024-10-16 | Swayze Eric (EVP Research) | Sale | 53 | 38.31 | 2,030 |
| 2024-10-15 | Swayze Eric (EVP Research) | Option Ex | 125 | .00 | 0 |
| 2024-08-29 | Geary Richard S (EVP, Chief Development Officer) | Sale | 331 | 49.63 | 16,427 |
| 2024-08-28 | Geary Richard S (EVP, Chief Development Officer) | Sale | 320 | 49.16 | 15,731 |
| 2024-08-05 | Geary Richard S (EVP, Chief Development Officer) | Sale | 2,430 | 48.00 | 116,640 |
| 2024-07-16 | Diaz Allene M. (Director) | Sale | 1,637 | 49.55 | 81,119 |
| 2024-07-16 | Klein Joseph Iii (Director) | Sale | 12,000 | 50.00 | 600,000 |
| 2024-07-16 | Klein Joseph Iii (Director) | Option Ex | 12,000 | 24.42 | 293,040 |
| 2024-07-15 | Diaz Allene M. (Director) | Option Ex | 4,677 | .00 | 0 |
| 2024-07-15 | Loscalzo Joseph (Director) | Option Ex | 4,677 | .00 | 0 |
| 2024-07-15 | Herman Joan E (Director) | Option Ex | 4,677 | .00 | 0 |
| 2024-07-15 | Berthelsen Spencer R (Director) | Option Ex | 4,677 | .00 | 0 |
| 2024-07-15 | Parshall B Lynne (Director) | Option Ex | 4,677 | .00 | 0 |
| 2024-07-15 | Wender Joseph H (Director) | Option Ex | 4,677 | .00 | 0 |
| 2024-06-17 | Berthelsen Spencer R (Director) | Sale | 16,000 | 40.29 | 644,640 |
| 2024-06-17 | Berthelsen Spencer R (Director) | Option Ex | 16,000 | 35.53 | 568,480 |
| 2024-05-09 | Wender Joseph H (Director) | Option Ex | 16,000 | 35.53 | 568,480 |
| 2024-05-03 | Klein Joseph Iii (Director) | Sale | 6,000 | 42.75 | 256,524 |
| 2024-04-16 | Birchler Brian (EVP, Corp and Development Ops) | Sale | 905 | 41.66 | 37,698 |
| 2024-04-16 | Baroldi Joseph (EVP, Chief Business Officer) | Sale | 4,006 | 41.60 | 166,641 |
| 2024-04-15 | Birchler Brian (EVP, Corp and Development Ops) | Option Ex | 1,875 | .00 | 0 |
| 2024-04-15 | Baroldi Joseph (EVP, Chief Business Officer) | Option Ex | 10,838 | .00 | 0 |
| 2024-02-16 | Monia Brett P (Chief Executive Officer) | Sale | 387 | 44.49 | 17,218 |
| 2024-02-02 | Schneider Eugene (EVP, Chf Clinical Develop Ofcr) | Sale | 2,071 | 49.59 | 102,700 |
| 2024-02-02 | Cadoret-manier Onaiza (EVP, Chf GL Pdt Str & Oper Ofc) | Sale | 2,125 | 49.60 | 105,404 |
| 2024-02-02 | Swayze Eric (EVP Research) | Sale | 1,907 | 49.56 | 94,512 |
| 2024-02-02 | O'neil Patrick R. (EVP CLO & General Counsel) | Sale | 1,961 | 49.67 | 97,410 |
| 2024-02-02 | Monia Brett P (Chief Executive Officer) | Sale | 23,501 | 49.37 | 1,160,314 |
| 2024-02-02 | Geary Richard S (EVP, Chief Development Officer) | Sale | 1,961 | 50.04 | 98,134 |
| 2024-02-02 | Hougen Elizabeth L (EVP, Finance & CFO) | Sale | 2,125 | 49.54 | 105,272 |
| 2024-02-02 | Bennett C Frank (EVP, Chief Scientific Officer) | Sale | 1,853 | 49.52 | 91,753 |
| 2024-01-31 | Swayze Eric (EVP Research) | Sale | 10,773 | 52.00 | 560,196 |
| 2024-01-25 | O'neil Patrick R. (EVP CLO & General Counsel) | Sale | 6,450 | 51.75 | 333,787 |
| 2024-01-25 | Monia Brett P (Chief Executive Officer) | Sale | 2,285 | 51.75 | 118,248 |
| 2024-01-17 | Birchler Brian (EVP, Corp and Development Ops) | Sale | 4,497 | 50.42 | 226,725 |
| 2024-01-17 | Schneider Eugene (EVP, Chf Clinical Develop Ofcr) | Sale | 5,482 | 50.42 | 276,385 |
| 2024-01-17 | Baroldi Joseph (EVP, Chief Business Officer) | Sale | 2,024 | 50.42 | 102,044 |
| 2024-01-17 | Cadoret-manier Onaiza (EVP, Chf GL Pdt Str & Oper Ofc) | Sale | 5,564 | 50.42 | 280,520 |
| 2024-01-17 | Swayze Eric (EVP Research) | Sale | 6,305 | 50.42 | 317,879 |
| 2024-01-17 | O'neil Patrick R. (EVP CLO & General Counsel) | Sale | 7,744 | 50.42 | 390,429 |
| 2024-01-17 | Monia Brett P (Chief Executive Officer) | Sale | 32,059 | 50.42 | 1,616,318 |
| 2024-01-17 | Geary Richard S (EVP, Chief Development Officer) | Sale | 7,338 | 50.42 | 369,959 |
| 2024-01-17 | Hougen Elizabeth L (EVP, Finance & CFO) | Sale | 8,683 | 50.42 | 437,770 |
| 2024-01-17 | Bennett C Frank (EVP, Chief Scientific Officer) | Sale | 6,745 | 50.42 | 340,062 |
| 2024-01-16 | Birchler Brian (EVP, Corp and Development Ops) | Option Ex | 12,080 | .00 | 0 |
| 2024-01-16 | Schneider Eugene (EVP, Chf Clinical Develop Ofcr) | Option Ex | 15,162 | .00 | 0 |
| 2024-01-16 | Baroldi Joseph (EVP, Chief Business Officer) | Option Ex | 5,041 | .00 | 0 |
| 2024-01-16 | Cadoret-manier Onaiza (EVP, Chf GL Pdt Str & Oper Ofc) | Option Ex | 15,062 | .00 | 0 |
| 2024-01-16 | Swayze Eric (EVP Research) | Option Ex | 17,090 | .00 | 0 |
| 2024-01-16 | O'neil Patrick R. (EVP CLO & General Counsel) | Option Ex | 20,641 | .00 | 0 |
| 2024-01-16 | Monia Brett P (Chief Executive Officer) | Option Ex | 68,084 | .00 | 0 |
| 2024-01-16 | Geary Richard S (EVP, Chief Development Officer) | Option Ex | 19,852 | .00 | 0 |
| 2024-01-16 | Hougen Elizabeth L (EVP, Finance & CFO) | Option Ex | 22,487 | .00 | 0 |
| 2024-01-16 | Bennett C Frank (EVP, Chief Scientific Officer) | Option Ex | 18,314 | .00 | 0 |
| 2024-01-12 | Schneider Eugene (EVP, Chf Clinical Develop Ofcr) | Sale | 8,000 | 53.50 | 428,000 |
| 2024-01-12 | Schneider Eugene (EVP, Chf Clinical Develop Ofcr) | Option Ex | 8,000 | 32.60 | 260,800 |
| 2023-12-28 | Birchler Brian (EVP, Corp and Development Ops) | Option Ex | 11,500 | 47.34 | 544,410 |
| 2023-12-28 | Swayze Eric (EVP Research) | Sale | 27,100 | 50.19 | 1,360,094 |
| 2023-12-28 | Swayze Eric (EVP Research) | Option Ex | 27,100 | 47.34 | 1,282,914 |
| 2023-12-28 | Hougen Elizabeth L (EVP, Finance & CFO) | Option Ex | 45,225 | 47.34 | 2,140,951 |
| 2023-12-28 | Parshall B Lynne (Director) | Sale | 42,525 | 50.19 | 2,134,244 |
| 2023-12-28 | Parshall B Lynne (Director) | Option Ex | 42,525 | 47.34 | 2,013,133 |
| 2023-12-27 | Parshall B Lynne (Director) | Sale | 50,000 | 50.23 | 2,511,500 |
| 2023-12-27 | Parshall B Lynne (Director) | Option Ex | 50,000 | 47.34 | 2,367,000 |
| 2023-12-26 | Schneider Eugene (EVP, Chf Clinical Develop Ofcr) | Sale | 25,000 | 51.46 | 1,286,575 |
| 2023-12-26 | Schneider Eugene (EVP, Chf Clinical Develop Ofcr) | Option Ex | 25,000 | 47.34 | 1,183,500 |
| 2023-12-26 | O'neil Patrick R. (EVP CLO & General Counsel) | Sale | 20,825 | 51.46 | 1,071,716 |
Insider trading activities including stock purchases, stock sales, and option exercises
of IONS listed in the above tables cannot be completely guaranteed as to their accuracy.
For more insider trading information of Ionis Pharmaceuticals Inc (symbol IONS,
CIK number 874015) see
the Securities and Exchange Commission (SEC) website.